MedTrace Logo

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-12-19

No results posted yet for this study

Summary

This is a multi-center, open-label, non-randomized, phase I study

Conditions

  • Advanced or Metastatic Breast Cancer

Interventions

DRUG

LEE011

3 weeks on and 1 week off

DRUG

Buparlisib

daily

DRUG

Letrozole

2.5 mg daily;

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-27
Primary Completion
2016-10-26
Completion
2016-10-26
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02154776 on ClinicalTrials.gov